title: Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study.
abstract: OBJECTIVE
  To examine whether decreased serum levels of adiponectin are an independent risk factor for the progression to type 2 diabetes in a Japanese population.
  
  
  METHODS
  The serum levels of adiponectin and tumor necrosis factor-alpha (TNF-alpha) at baseline (from 1995 to 1997) were evaluated in 1,792 individuals (1,023 women and 769 men, aged 58.5 +/- 12.5 years) from a cohort population (n = 3,706) of the Funagata study. Glucose tolerance was evaluated at baseline and also at 5-year follow-up examinations (n = 978, follow-up rate, 54.6%) according to the 1985 World Health Organization criteria. The correlation of clinical traits with serum levels of adiponectin was examined. The association of the traits with the progression to type 2 diabetes at the 5-year follow-up was also examined.
  
  
  RESULTS
  Among the traits examined, the correlation with aging was highest (r = 0.312, P < 0.001). Eighteen subjects with normal glucose tolerance (NGT) developed diabetes, and 709 remained NGT at the 5-year follow-up examinations. The subjects who became diabetic had decreased serum levels of adiponectin (7.29 +/- 2.35 vs. 9.13 +/- 2.35 10 x log microg/ml, P = 0.009). Multiple logistic regression analysis with age, sex, waist-to-hip ratio, and 2-h plasma glucose as the variables revealed that serum adiponectin level (odds ratio [per 0.1 log microg/ml] 0.766, P = 0.029) was an independent risk factor for the progression to type 2 diabetes. The subjects whose serum levels of adiponectin were in the lowest tertile were 9.320 times (95% CI 1.046-83.1) more likely to develop diabetes than those in the highest tertile (P = 0.046).
  
  
  CONCLUSIONS
  Decreased serum adiponectin level is an independent risk factor for progression to type 2 diabetes.
authors.affiliation: Third Department of Internal Medicine, Yamagata University School of Medicine, Yamagata, Japan. mdaimon@med.id.yamagata-u.ac.jp
authors.forename: Makoto
authors.initials: M
authors.lastname: Daimon
authors.forename: Toshihide
authors.initials: T
authors.lastname: Oizumi
authors.forename: Tamotsu
authors.initials: T
authors.lastname: Saitoh
authors.forename: Wataru
authors.initials: W
authors.lastname: Kameda
authors.forename: Akihiko
authors.initials: A
authors.lastname: Hirata
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yamaguchi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ohnuma
authors.forename: Masahiko
authors.initials: M
authors.lastname: Igarashi
authors.forename: Makoto
authors.initials: M
authors.lastname: Tominaga
authors.forename: Takeo
authors.initials: T
authors.lastname: Kato
mesh_terms: D052242:Adiponectin; D044466:Asian People; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure; D015992:Body Mass Index; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000453:epidemiology*; D018450:Disease Progression; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D007564:Japan; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D011506:Proteins / Q000378:metabolism*; D012307:Risk Factors
chemical_list: D052242:Adiponectin; D015415:Biomarkers; D036341:Intercellular Signaling Peptides and Proteins; D008055:Lipids; D011506:Proteins